Halozyme Therapeutics (NASDAQ:HALO)
Q2 2014 Earnings Call
August 11, 2014 4:30 pm ET
Schond Greenway -
Helen I. Torley - Chief Executive Officer, President and Director
David A. Ramsay - Chief Financial Officer,...
Halozyme Therapeutics is expected to book a narrower loss than a year ago when it reports second-quarter earnings on Monday, August 11, 2014. Analysts are expecting a loss of 18 cents per share, up from a loss of 20 cents per share a year...
Halozyme Therapeutics (NASDAQ: HALO) received notice Thursday that the Blood Products Advisory Committee (BPAC) of the U.S. Food and Drug Administration voted in favor of HyQvia, which it was working with along with Baxter (NYSE: BAX).
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in
its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with
pancreatic cancer under the revised clinical protocol...
Analysts at JP Morgan initiated coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Outperform rating.
The target price for Halozyme Therapeutics is set to $13.
Halozyme Therapeutics shares have gained 10.07% over the past 52 weeks,...
NEW YORK (TheStreet) -- RATINGS CHANGES
Halozyme Therapeutics was upgraded at UBS to buy from neutral, UBS said. Driven on pipeline potential and undervalued valuation, UBS said. Twelve-month price target is $16.
Hewlett-Packard was upgraded...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.